{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:00:18Z","timestamp":1794088818593,"version":"4.8.0"},"reference-count":47,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Abnormal metabolic reprogramming is a hallmark of acute myeloid leukemia (AML), contributing to leukemia initiation, progression and drug resistance. The key mitochondrial citrate transporter SLC25A1 plays an essential role in regulating cellular energy metabolism and plays an important role in the regulation of lipid metabolism. However, the role of SLC25A1 in the pathogenesis and aberrant lipid metabolism in AML remain unexplored. In this study, our analysis of public datasets and patient samples revealed that SLC25A1 expression was markedly elevated in AML and was associated with poor prognosis. Knockdown or pharmacological inhibition of SLC25A1 significantly suppressed AML cell proliferation by inducing apoptosis, without affecting cell cycle progression or differentiation. Moreover, SLC25A1 proved vital for AML tumorigenesis in vivo. Mechanistically, we demonstrated that SLC25A1 inhibition disrupted citrate homeostasis, leading to mitochondrial dysfunction and reduced fatty acid metabolism. Notably, we developed a novel SLC25A1 inhibitor, CTPI3, which effectively inhibits the progression of AML in vivo, and synergizes with venetoclax to kill AML cells by mitochondrial and fatty acid metabolism regulation. In summary, our findings highlight that SLC25A1 plays a vital role in maintaining AML cell survival and regulating its drug sensitivity. Furthermore we developed a more effective novel drug targeting SLC25A1, providing additional therapeutic options for venetoclax-resistant patients and highlighting SLC25A1 as a promising biomarker and therapeutic target for AML.<\/jats:p>","DOI":"10.3324\/haematol.2024.287269","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T07:52:50Z","timestamp":1756972370000},"page":"1220-1234","source":"Crossref","is-referenced-by-count":8,"title":["SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia"],"prefix":"10.3324","volume":"111","author":[{"given":"Miao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjie","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Him","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"87502","doi-asserted-by":"crossref","unstructured":"Chen X, Glytsou C, Zhou H. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019; 9(7):890-909.","DOI":"10.1158\/2159-8290.CD-19-0117"},{"key":"87503","doi-asserted-by":"crossref","unstructured":"MacPherson L, Anokye J, Yeung M. HBO1 is required for the maintenance of leukaemia stem cells. Nature. 2020; 577(7789):266-270.","DOI":"10.1038\/s41586-019-1835-6"},{"key":"87504","doi-asserted-by":"crossref","unstructured":"Miller K, Nogueira L, Mariotto A. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69(5):363-385.","DOI":"10.3322\/caac.21565"},{"key":"87505","doi-asserted-by":"crossref","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017; 168(4):657-669.","DOI":"10.1016\/j.cell.2016.12.039"},{"key":"87506","doi-asserted-by":"crossref","unstructured":"DeBerardinis RJ, Chandel NS. We need to talk about the Warburg effect. Nat Metab. 2020; 2(2):127-129.","DOI":"10.1038\/s42255-020-0172-2"},{"key":"87507","doi-asserted-by":"crossref","unstructured":"Sharon D, Cathelin S, Mirali S. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019; 11(516):eaax2863.","DOI":"10.1126\/scitranslmed.aax2863"},{"key":"87508","doi-asserted-by":"crossref","unstructured":"Skrti\u0107 M, Sriskanthadevan S, Jhas B. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20(5):674-688.","DOI":"10.1016\/j.ccr.2011.10.015"},{"key":"87509","doi-asserted-by":"crossref","unstructured":"Farge T, Saland E, de Toni F. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017; 7(7):716-735.","DOI":"10.1158\/2159-8290.CD-16-0441"},{"key":"87510","doi-asserted-by":"crossref","unstructured":"Samudio I, Harmancey R, Fiegl M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010; 120(1):142-156.","DOI":"10.1172\/JCI38942"},{"key":"87511","doi-asserted-by":"crossref","unstructured":"Perland E, Fredriksson R. Classification systems of secondary active transporters. Trends Pharmacol Sci. 2017; 38(3):305-315.","DOI":"10.1016\/j.tips.2016.11.008"},{"key":"87512","doi-asserted-by":"crossref","unstructured":"Elena P, Gert F, Mikko G. The role of solute carrier transporters in efficient anticancer drug delivery and therapy. Pharmaceutics. 2023; 15(2):364.","DOI":"10.3390\/pharmaceutics15020364"},{"key":"87513","doi-asserted-by":"crossref","unstructured":"Palmieri F, Monn\u00e9 M. Discoveries, metabolic roles and diseases of mitochondrial carriers: a review. Biochim Biophys Acta. 2016; 1863(10):2362-2378.","DOI":"10.1016\/j.bbamcr.2016.03.007"},{"key":"87514","doi-asserted-by":"crossref","unstructured":"Palmieri F. Mitochondrial transporters of the SLC25 family and associated diseases: a review. J Inherit Metab Dis. 2014; 37(4):565-575.","DOI":"10.1007\/s10545-014-9708-5"},{"key":"87515","doi-asserted-by":"crossref","unstructured":"Palmieri F. The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol Aspects Med. 2013; 34","DOI":"10.1016\/j.mam.2012.05.005"},{"key":"87516","doi-asserted-by":"crossref","unstructured":"Ma C, Gerhard E, Lu D, Yang J. Citrate chemistry and biology for biomaterials design. Biomaterials. 2018; 178:383-400.","DOI":"10.1016\/j.biomaterials.2018.05.003"},{"key":"87517","doi-asserted-by":"crossref","unstructured":"Zhang Z, Qiao Y, Sun Q, Peng L, Sun L. A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability. Cell Death Discov. 2023; 9(1):350.","DOI":"10.1038\/s41420-023-01640-6"},{"key":"87518","doi-asserted-by":"crossref","unstructured":"Fernandez HR, Gadre SM, Tan M. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 2018; 25(7):1239-1258.","DOI":"10.1038\/s41418-018-0101-z"},{"key":"87519","doi-asserted-by":"crossref","unstructured":"Ozkaya AB, Ak H, Atay S, Aydin HH. Targeting mitochondrial citrate transport in breast cancer cell lines. Anticancer Agents Med Chem. 2015; 15(3):374-381.","DOI":"10.2174\/1871520615666141216150659"},{"key":"87520","doi-asserted-by":"crossref","unstructured":"Yang Y, He J, Zhang B. SLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer. Cell Death Dis. 2021; 12(12):1108.","DOI":"10.1038\/s41419-021-04411-2"},{"key":"87521","doi-asserted-by":"crossref","unstructured":"Lee J, Khan D, Hurren R. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood. 2021; 138(3):234-245.","DOI":"10.1182\/blood.2020009081"},{"key":"87522","doi-asserted-by":"crossref","unstructured":"Chiou J, Huang N, Huang C. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. J Cell Physiol. 2021; 236(11):7356-7375.","DOI":"10.1002\/jcp.30407"},{"key":"87523","doi-asserted-by":"crossref","unstructured":"Tyner J, Tognon C, Bottomly D. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018; 562(7728):526-531.","DOI":"10.1038\/s41586-018-0623-z"},{"key":"87524","doi-asserted-by":"crossref","unstructured":"Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019; 20(3):137-155.","DOI":"10.1038\/s41580-018-0085-z"},{"key":"87525","doi-asserted-by":"crossref","unstructured":"Dias S, Soares V, Ferreira A. Lipid droplets fuel SARSCoV-2 replication and production of inflammatory mediators. PLoS Pathog. 2020; 16(12):e1009127.","DOI":"10.1371\/journal.ppat.1009127"},{"key":"87526","doi-asserted-by":"crossref","unstructured":"Zhou J, Simon J, Liao C. An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. Mol Cell. 2022; 82(16):3030-3044.e8.","DOI":"10.1016\/j.molcel.2022.06.003"},{"key":"87527","doi-asserted-by":"crossref","unstructured":"Mishra S, Millman S, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023; 141(10):1119-1135.","DOI":"10.1182\/blood.2022018092"},{"key":"87528","doi-asserted-by":"crossref","unstructured":"Egan G, Schimmer A. Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis. Trends Cell Biol. 2023; 33(6):455-462.","DOI":"10.1016\/j.tcb.2022.11.004"},{"key":"87529","doi-asserted-by":"crossref","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022; 12(1):31-46.","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"87530","doi-asserted-by":"crossref","unstructured":"Yangjing Z, Xia L, Fusheng S. Citrate promotes excessive lipid biosynthesis and senescence in tumor cells for tumor therapy. Adv Sci (Weinh). 2021; 9(1):e2101553.","DOI":"10.1002\/advs.202101553"},{"key":"87531","doi-asserted-by":"crossref","unstructured":"Mosaoa R, Kasprzyk-Pawelec A, Fernandez H, Avantaggiati M. The mitochondrial citrate carrier SLC25A1\/CIC and the fundamental role of citrate in cancer, inflammation and beyond. Biomolecules. 2021; 11(2):141.","DOI":"10.3390\/biom11020141"},{"key":"87532","doi-asserted-by":"crossref","unstructured":"Hlouschek J, Hansel C, Jendrossek V, Matschke J. The mitochondrial citrate carrier (SLC25A1) sustains redox homeostasis and mitochondrial metabolism supporting radioresistance of cancer cells with tolerance to cycling severe hypoxia. Front Oncol. 2018; 8:170.","DOI":"10.3389\/fonc.2018.00170"},{"key":"87533","doi-asserted-by":"crossref","unstructured":"Liu F, Deng S, Li Y, Du J, Zeng H. SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients. Front Genet. 2022; 13:1081262.","DOI":"10.3389\/fgene.2022.1081262"},{"key":"87534","doi-asserted-by":"crossref","unstructured":"Lee K, Giltnane J, Balko J. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017; 26(4):633-647.e7.","DOI":"10.1016\/j.cmet.2017.09.009"},{"key":"87535","doi-asserted-by":"crossref","unstructured":"Hattori A, Tsunoda M, Konuma T. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature. 2017; 545(7655):500-504.","DOI":"10.1038\/nature22314"},{"key":"87536","doi-asserted-by":"crossref","unstructured":"Ye H, Adane B, Khan N. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell stem cell. 2016; 19(1):23-37.","DOI":"10.1016\/j.stem.2016.06.001"},{"key":"87537","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Reyes I, Chandel N. Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680.","DOI":"10.1038\/s41568-021-00378-6"},{"key":"87538","doi-asserted-by":"crossref","unstructured":"Yashi M, Guoyuan Q, Francesca V. Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration. Nat Metab. 2023; 5(3):445-465.","DOI":"10.1038\/s42255-023-00756-4"},{"key":"87539","doi-asserted-by":"crossref","unstructured":"Shao X, Xu A, Du W. The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML. Blood. 2023; 142(4):365-381.","DOI":"10.1182\/blood.2022019056"},{"key":"87540","doi-asserted-by":"crossref","unstructured":"Lee S, Li J, Tai J, Ratliff T, Park K, Cheng J. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. ACS Nano. 2015; 9(3):2420-2432.","DOI":"10.1021\/nn504025a"},{"key":"87541","doi-asserted-by":"crossref","unstructured":"Zhang R, Peng X, Du J. Oncogenic KRASG12D reprograms lipid metabolism by upregulating SLC25A1 to drive pancreatic tumorigenesis. Cancer Res. 2023; 83(22):3739-3752.","DOI":"10.1158\/0008-5472.CAN-22-2679"},{"key":"87542","doi-asserted-by":"crossref","unstructured":"Chan S, Thomas D, Corces-Zimmerman M. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015; 21(2):178-184.","DOI":"10.1038\/nm.3788"},{"key":"87543","doi-asserted-by":"crossref","unstructured":"DiNardo C, Tiong I, Quaglieri A. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803.","DOI":"10.1182\/blood.2019003988"},{"key":"87544","doi-asserted-by":"crossref","unstructured":"Jones C, Stevens B, D\u2019Alessandro A. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018; 34(5):724-740.e4.","DOI":"10.1016\/j.ccell.2018.10.005"},{"key":"87545","doi-asserted-by":"crossref","unstructured":"Thomalla D, Beckmann L, Grimm C. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022; 140(20):2113-2126.","DOI":"10.1182\/blood.2021014304"},{"key":"87546","doi-asserted-by":"crossref","unstructured":"Li X, Xu S, Tan Y, Chen J. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. Cochrane Database Syst Rev. 2015; 2015(6):CD010432.","DOI":"10.1002\/14651858.CD010432.pub2"},{"key":"87547","doi-asserted-by":"crossref","unstructured":"Zhang X, Yang L, Liu X. Regulatory role of RBM39 in acute myeloid leukemia: mediation through the PI3K\/AKT pathway. Biochim Biophys Acta Mol Cell Res. 2024; 1871(1):119607.","DOI":"10.1016\/j.bbamcr.2023.119607"},{"key":"87548","doi-asserted-by":"crossref","unstructured":"Stevens B, Jones C, Pollyea D. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020; 1(12):1176-1187.","DOI":"10.1038\/s43018-020-00126-z"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12250\/78784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12250\/79859","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12250\/78784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:09:41Z","timestamp":1794046181000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287269","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}